(Q33946920)

30 July 2017

1 reference

title

HIV-1 protease inhibitors. (English)

1 reference

30 July 2017

1

Eron JJ Jr

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Clinical Infectious Diseases

30 July 2017

published in

1 reference

30 July 2017

volume

30 Suppl 2

1 reference

30 July 2017

page(s)

S160-70

1 reference

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

30 July 2017

cites work

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

21 January 2018

HIV-protease inhibitors

1 reference

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

21 January 2018

1 reference

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

21 January 2018

1 reference

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

HIV viral load markers in clinical practice

21 January 2018

1 reference

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

21 January 2018

1 reference

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

21 January 2018

1 reference

Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy

21 January 2018

1 reference

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.

21 January 2018

1 reference

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

21 January 2018

1 reference

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

21 January 2018

1 reference

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

21 January 2018

1 reference

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

21 January 2018

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

Poor penetration of the male genital tract by HIV-1 protease inhibitors

21 January 2018

1 reference

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure

21 January 2018

1 reference

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens

21 January 2018

1 reference

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

21 January 2018

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

Indinavir-associated lipodystrophy.

21 January 2018

1 reference

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/313853

1 reference

30 July 2017

1 reference